News

Important information

BIOJAMP : A Range of Biosimilars for a Seamless Approach

May 15, 2023
JAMP Pharma Group receives Health Canada approval for Pr JAMP Dapagliflozin, a new generic alternative for the treatment of type 2 diabetes
November 15, 2022
The JAMP Pharma Group launches Pr JAMP Apremilast, a new generic alternative for the treatment of plaque psoriasis and psoriatic arthritis
June 7, 2022
Jason Frame Recognized by the Neighbourhood Pharmacy Association of Canada as Recipient of Distinguished Associate of the Year Award
May 19, 2022
JAMP Pharma Group Launches PrJAMP Teriflunomide, a New Generic for the Treatment of Patients with Relapsing-Remitting Multiple Sclerosis
February 28, 2022
JAMP Pharma Group launches a new generic drug for the treatment of attention deficit hyperactivity disorder (ADHD)
February 1, 2022
BIOJAMP: A Range of Biosimilars for a Seamless Approach